HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Related Collections Related Article Social Bookmarking                What's this?

Screening for Type 2 Diabetes

Abbreviations: DPP, Diabetes Prevention Program • FPG, fasting plasma glucose • GDM, gestational diabetes mellitus • IFG, impaired fasting glucose • IGT, impaired glucose tolerance • OGTT, oral glucose tolerance test

The first 300 words of the full text of this article appear below.

	INTRODUCTION

 
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Type 2 diabetes, the most prevalent form of the disease, is often asymptomatic in its early stages and can remain undiagnosed for many years.

The chronic hyperglycemia of diabetes is associated with long-term dysfunction, damage, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. Individuals with undiagnosed type 2 diabetes are also at significantly higher risk for stroke, coronary heart disease, and peripheral vascular disease than the nondiabetic population. They also have a greater likelihood of having dyslipidemia, hypertension, and obesity. Because early detection and prompt treatment may reduce the burden of diabetes and its complications, screening for diabetes may be appropriate under certain circumstances. This position statement provides recommendations for diabetes screenings performed in physicians’ offices and in other health care settings.

This position statement does not address screening for type 1 diabetes or gestational diabetes mellitus (GDM). Because of the acute onset of symptoms, most cases of type 1 diabetes are detected soon after symptoms develop. Widespread clinical testing of asymptomatic individuals for the presence of autoantibodies related to type 1 diabetes cannot be recommended at this time as a means to identify persons at risk. Reasons for this include the following: 1) cutoff values for some of the immune marker assays have not been completely established in clinical settings; 2) there is no consensus as to what action should be taken when a positive autoantibody test result is obtained; and 3) because the incidence of type 1 diabetes is low, testing of healthy children will identify only a very small number (<0.5%) who at that moment may be "prediabetic." Clinical studies are being conducted to test various methods . . . [Full Text of this Article]

	DIABETES PREVALENCE AND RISK FACTORS

 

	PRINCIPLES TO ASSESS THE VALUE OF SCREENING FOR TYPE 2 DIABETES

 

	GENERAL RECOMMENDATIONS FOR THE EVALUATION OF HIGH-RISK INDIVIDUALS

 

	TESTS

 

	OTHER CONSIDERATIONS

 

	COMMUNITY SCREENING

 

	CONCLUSION

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article:

POSITION STATEMENTS & ADA STATEMENTS
Diabetes Care 2006 29: S75-S77. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				T. J. Orchard, M. Temprosa, R. Goldberg, S. Haffner, R. Ratner, S. Marcovina, S. Fowler, and for the Diabetes Prevention Program Research Group The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial Ann Intern Med, April 19, 2005; 142(8): 611 - 619. [Abstract] [Full Text] [PDF]

				R. P. Trevino, Z. Yin, A. Hernandez, D. E. Hale, O. A. Garcia, and C. Mobley Impact of the Bienestar School-Based Diabetes Mellitus Prevention Program on Fasting Capillary Glucose Levels: A Randomized Controlled Trial Arch Pediatr Adolesc Med, September 1, 2004; 158(9): 911 - 917. [Abstract] [Full Text] [PDF]

				Centers for Disease Control and Prevention Primary Primary Prevention of Type 2 Diabetes Mellitus by Lifestyle Intervention: Implications for Health Policy Ann Intern Med, June 1, 2004; 140(11): 951 - 957. [Abstract] [Full Text] [PDF]